The plasma clearance of an albumin/acrolein (107028) adduct was studied in rats. Male Sprague-Dawley-rats were injected intravenously with 10 milligrams (mg) of native tritium (H3) labeled albumin or an albumin/acrolein adduct previously formed by reacting 5mg/ml albumin with 5 millimolar acrolein. Blood samples were collected at various times up to 33 hours post injection and assayed for H3 activity. The rate of clearance of albumin derived radioactivity from the animals was calculated from the data. The rats were killed after 33 hours and the blood, liver, kidneys, and spleen were collected and assayed for H3 activity. Other plasma, liver, kidney, and spleen samples were precipitated with trichloroacetic-acid (TCA) and the TCA soluble and insoluble fractions were analyzed for radioactivity. Albumin derived H3 activity was cleared significantly faster from the plasma of rats injected with the albumin/acrolein adduct than from those injected with native albumin, 68% versus 48% being cleared after 11 hours and 78% versus 68% being cleared after 33 hours. More than 90% of the plasma radioactivity was associated with the albumin and only 10% with the globulin fraction in all groups. The amounts of radioactivity in the whole liver, kidney, and spleen were higher in rats injected with the albumin/acrolein adduct than in those injected with native albumin; however, only the increase in the kidney was statistically significant. The TCA soluble fractions of kidney and liver tissues from rats injected with acrolein adducted albumin contained more radioactivity than those from rats injected with native albumin. The reverse was true for the TCA insoluble fraction of these tissues. The distribution of radioactivity between the TCA insoluble and soluble fractions of the spleen was similar for albumin/acrolein adduct and native albumin injected rats. The authors conclude that the albumin/acrolein adduct is cleared more rapidly from the circulation and degraded more rapidly by the liver and kidney than native albumin. The rate of plasma clearance of protein adducts must be considered when contemplating their use as exposure markers.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.